16S rRNA gene sequencing of rectal swab in patients affected by COVID-19Original paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined the gut microbiota of patients with COVID-19 pneumonia using 16S rRNA gene sequencing performed on rectal swabs. Researchers compared microbial composition and diversity between patients treated in the intensive care unit (i-COVID19), patients treated in infectious disease wards (w-COVID19), and healthy controls (CTRL). The goal was to characterize how gut microbial communities differ across varying levels of COVID-19 disease severity.
Who was studied?
The study population consisted of patients hospitalized with COVID-19 pneumonia, divided into two groups by care setting: those admitted to the intensive care unit and those managed in infectious disease wards. These two patient groups were compared against a control group without COVID-19. The abstract does not report exact sample sizes, ages, or other demographic details for these cohorts.
What were the most important findings?
Patients in the ICU showed a decrease in the Chao1 index compared to both controls and ward patients, indicating lower microbial richness in the most severely ill patients, while the Shannon index showed no significant change. At the phylum level, ward patients showed an increase in Proteobacteria compared to controls. Fusobacteria and Spirochetes were both decreased relative to controls, with Spirochetes showing the greatest decrease in ICU patients specifically.
What are the greatest implications of this study?
The findings indicate that gut microbial communities shift in composition and richness according to COVID-19 disease severity, with the most pronounced changes occurring in critically ill ICU patients. These preliminary results suggest the gut microbiota may hold promising biomarkers for diagnosing COVID-19 and gauging disease severity. The authors note that validation in larger cohorts could support using microbiota profiles to help stratify patients by severity.